Evidence File 043 · Resveratrol · Method v0.14 of 4 claims researched

ResveratrolTrans-resveratrol · 4 claims

The mechanism it was famous for turned out not to be the mechanism. Almost nothing downstream has held up in humans.

4Claims scored

8Sources

300–1000 mgStudied dose

Jul 26Reviewed

Claim 01

Improves cholesterol, triglycerides and blood sugar

3.6/10

Weak·Null across every marker · zero heterogeneity

A GRADE-appraised meta-analysis in people with obesity or overweight found no significant effect on triglycerides (SMD 0.11, 95% CI −0.14 to 0.35, p=0.39, I²=0%), total cholesterol (SMD 0.04, −0.26 to 0.33, p=0.82, I²=0%) or HbA1c (SMD 0.00, −0.99 to 1.00, p=0.99).

A separate meta-analysis of over 700 adults found no significant differences in LDL or HDL cholesterol. A meta-analysis of ten trials and 698 subjects found no effect on bone mineral density at any site, and no change in six separate bone turnover markers.

On cognition, a systematic review asked in its title whether resveratrol is a miracle drug in neuropsychiatry or a cognitive enhancer for mice only. Promising animal effects have not replicated in humans, where associations with cognition and mood are weak at best.

The working

1Quantity

5Quality

1Consistency

9Directness

(1 × 0.25) + (5 × 0.35) + (1 × 0.25) + (9 × 0.15) = 3.6
Scored as support for the claim. The nulls are unusually clean, with I² at 0% on two of three outcomes — the trials agree that nothing happened.

MetaEffect of resveratrol supplementation on metabolic risk markers and anthropometric parameters in individuals with obesity or overweight 5 trials, 419 participants · GRADE appraised
MetaEffects of resveratrol supplementation on bone quality: systematic review and meta-analysis of RCTs 10 studies, 698 subjects · doi 10.1186/s12906-021-03381-4
RevResveratrol: a miracle drug in neuropsychiatry or a cognitive enhancer for mice only? Systematic review and meta-analysis Animal effects not replicated in humans

Claim 02

Lowers blood pressure at higher doses

4.8/10

Emerging·The one place a signal survives

Blood pressure effects appear in trials using 300 mg/day for at least three months, or 600–1000 mg/day for two to three months. Doses as low as 75 mg/day produced no significant effect on either systolic or diastolic pressure.

An individual trial in 46 people with type 2 diabetes taking 800 mg/day for two months reported reductions versus placebo of 10.2 mmHg systolic and 7.3 mmHg diastolic. An earlier meta-analysis of six studies and 247 subjects examined the same question with less encouraging results.

Reviews of vascular outcomes describe the randomised evidence as contrasting, without a dose-dependent effect. This is a signal worth following, not a demonstrated benefit.

The working

4Quantity

4Quality

4Consistency

9Directness

(4 × 0.25) + (4 × 0.35) + (4 × 0.25) + (9 × 0.15) = 4.8
Included because it is the strongest surviving claim, not because it is strong. Dose-dependence is at least consistent.

MetaResveratrol effects on metabolic syndrome features: systematic review and meta-analysis Dose and duration thresholds for blood pressure effects
RevResveratrol and vascular health: evidence from clinical studies and mechanisms related to metabolites produced by gut microbiota Contrasting RCT results without dose-dependent effect

Claim 03

Works by activating sirtuins

3.2/10

Evidence against·The founding mechanism did not survive

Resveratrol was initially believed to activate sirtuins, and that hypothesis is what made it a longevity compound rather than a wine component. Subsequent work, including studies using CRISPR, showed resveratrol does not directly activate sirtuins and may instead induce cellular stress.

This is the most important thing on the page and the least widely known. It is not a case of a mechanism that works but produces small effects. The proposed mechanism itself did not hold, which explains rather neatly why the human outcomes never arrived.

The working

1Quantity

5Quality

1Consistency

6Directness

(1 × 0.25) + (5 × 0.35) + (1 × 0.25) + (6 × 0.15) = 3.2
Scored as support for the claim. The entire longevity thesis was built on this and later work using CRISPR did not support it.

RevResveratrol and aging: review of longevity claims and scientific findings Sirtuin activation hypothesis not supported by subsequent CRISPR-based work

Claim 04

Red wine’s cardiovascular benefits come from its resveratrol

2.9/10

Evidence against·The dose relationship runs backwards

Here is the awkward finding. Reviewing the vascular trials, studies delivering resveratrol through food sources such as red wine reported significant effects despite containing far less resveratrol on average than tablet supplementation — while studies using often extreme supplemental doses produced null findings.

If resveratrol were the active agent, the dose-response should run the other way. That it runs backwards suggests whatever red wine studies were picking up, it was probably not the resveratrol.

The pharmacology fits. Oral resveratrol shows high absorption but very low bioavailability in humans — it is absorbed and then rapidly conjugated, so what circulates is largely metabolites.

The working

1Quantity

5Quality

1Consistency

7Directness

(1 × 0.25) + (5 × 0.35) + (1 × 0.25) + (7 × 0.15) = 2.9
Scored as support for the claim. The pattern in the trial literature is the opposite of what the hypothesis predicts.

RevResveratrol and vascular health: food source versus supplemental dose findings Food-source studies positive at lower content; high-dose supplementation null
PKWalle T, Hsieh F, DeLegge MH, et al. High absorption but very low bioavailability of oral resveratrol in humans, as cited Drug Metab Dispos 2004;32:1377-1382

Dosage as studied

Most-studied regimen

300–1000 mg per day where any effect appears

Doses of 75 mg/day showed nothing. The red wine that started this contains a tiny fraction of any of these amounts.

Where signal appears: Blood pressure effects were reported mainly at 300 mg/day for at least three months, or 600–1000 mg/day for two to three months.
Where it does not: 75 mg/day for 45 days or three months had no significant effect on systolic or diastolic pressure.
Bioavailability: High absorption, very low bioavailability. Most of what is absorbed is rapidly conjugated and what circulates is metabolites, not resveratrol.
Formulation: Trials vary between pure trans-resveratrol and extracts, which the reviewers flag as a limitation on pooling them.